Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab | Zendy

Camille Hua | Zendy; Lise Boussemart | Zendy; Christine Mateus | Zendy; Émilie Routier | Zendy; C. Boutros | Zendy; H. Cazenave | Zendy; R. Viollet | Zendy; M. Thomas | Zendy; Séverine Le Roy | Zendy; Naima Benannoune | Zendy; Gorana Tomasic | Zendy; JeanCharles Soria | Zendy; Stéphane Champiat | Zendy; Matthieu Texier | Zendy; Émilie Lanoy | Zendy; Caroline Robert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Author(s) -

Camille Hua,

Lise Boussemart,

Christine Mateus,

Émilie Routier,

C. Boutros,

H. Cazenave,

R. Viollet,

M. Thomas,

Séverine Le Roy,

Naima Benannoune,

Gorana Tomasic,

JeanCharles Soria,

Stéphane Champiat,

Matthieu Texier,

Émilie Lanoy,

Caroline Robert

Publication year - 2015

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2015.2707

Subject(s) - medicine , vitiligo , pembrolizumab , context (archaeology) , dermatology , melanoma , oncology , immunotherapy , cancer , cancer research , paleontology , biology

Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo with tumor response in patients with melanoma who undergo immunotherapy has been reported but is still controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research